| Dr Rick J Geier, MD | |
|
820 5th St N, Carrington, ND 58421-1223 | |
| (701) 652-2515 | |
| (701) 652-2846 |
| Full Name | Dr Rick J Geier |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 46 Years |
| Location | 820 5th St N, Carrington, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063499804 | NPI | - | NPPES |
| 11603 | Other | ND | BLUE CROSS BLUE SHIELD ND |
| 18187 | Medicaid | ND | |
| 407241030699 | Other | ND | PREFERREDONE |
| 792012178 | Other | ND | RAIL ROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 4089 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi Health At Home | Valley city, ND | Home health agency |
| St Aloisius Medical Center | Harvey, ND | Hospital |
| Carrington Health Center | Carrington, ND | Hospital |
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Heart Of America Medical Center | Rugby, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Aloisius Hospital Inc | 6002802378 | 12 |
News Archive
Researchers in Italy have conducted a study showing that patients who had tested positive for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still had neutralizing antibodies against the virus 10 months later.
It's a scenario played out all too frequently: Adult children, worried about the safety of their aging parents, foist devices on them to monitor their safety. And their parents, resentful of having their privacy invaded and losing their independence, resist fiercely.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
Deakin neuro-engineers have conducted an investigation into how mosquito brains are affected by the Zika virus, in a breakthrough study that could crack the code to creating a viable vaccine.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 9 days ago
| Entity Name | St Aloisius Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457477218 PECOS PAC ID: 6002802378 Enrollment ID: O20040422000286 |
News Archive
Researchers in Italy have conducted a study showing that patients who had tested positive for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still had neutralizing antibodies against the virus 10 months later.
It's a scenario played out all too frequently: Adult children, worried about the safety of their aging parents, foist devices on them to monitor their safety. And their parents, resentful of having their privacy invaded and losing their independence, resist fiercely.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
Deakin neuro-engineers have conducted an investigation into how mosquito brains are affected by the Zika virus, in a breakthrough study that could crack the code to creating a viable vaccine.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 9 days ago
| Entity Name | Carrington Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558389338 PECOS PAC ID: 0547177552 Enrollment ID: O20040810000314 |
News Archive
Researchers in Italy have conducted a study showing that patients who had tested positive for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still had neutralizing antibodies against the virus 10 months later.
It's a scenario played out all too frequently: Adult children, worried about the safety of their aging parents, foist devices on them to monitor their safety. And their parents, resentful of having their privacy invaded and losing their independence, resist fiercely.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
Deakin neuro-engineers have conducted an investigation into how mosquito brains are affected by the Zika virus, in a breakthrough study that could crack the code to creating a viable vaccine.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 9 days ago
| Entity Name | St Aloisius Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1457477218 PECOS PAC ID: 6002802378 Enrollment ID: O20080421000213 |
News Archive
Researchers in Italy have conducted a study showing that patients who had tested positive for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still had neutralizing antibodies against the virus 10 months later.
It's a scenario played out all too frequently: Adult children, worried about the safety of their aging parents, foist devices on them to monitor their safety. And their parents, resentful of having their privacy invaded and losing their independence, resist fiercely.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
Deakin neuro-engineers have conducted an investigation into how mosquito brains are affected by the Zika virus, in a breakthrough study that could crack the code to creating a viable vaccine.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rick J Geier, MD 820 5th St N, Po Box 79, Carrington, ND 58421-1223 Ph: (701) 652-2515 | Dr Rick J Geier, MD 820 5th St N, Carrington, ND 58421-1223 Ph: (701) 652-2515 |
News Archive
Researchers in Italy have conducted a study showing that patients who had tested positive for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still had neutralizing antibodies against the virus 10 months later.
It's a scenario played out all too frequently: Adult children, worried about the safety of their aging parents, foist devices on them to monitor their safety. And their parents, resentful of having their privacy invaded and losing their independence, resist fiercely.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
Deakin neuro-engineers have conducted an investigation into how mosquito brains are affected by the Zika virus, in a breakthrough study that could crack the code to creating a viable vaccine.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 9 days ago